Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Aware Super Pty Ltd as trustee of Aware Super

Key Points

• Aware Super Pty Ltd significantly reduced its holdings in Regeneron Pharmaceuticals by 63.3% in the second quarter, leaving it with 1,128 shares worth approximately $592,000.
• Regeneron Pharmaceuticals reported earnings of $12.89 per share for the last quarter, surpassing analysts' expectations, with revenue of $3.68 billion.
• Numerous analysts have set new price targets for Regeneron, with a consensus average price target of $817.88 and ratings ranging from "Strong Buy" to "Sell".

Aware Super Pty Ltd as trustee of Aware Super reduced its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 63.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,128 shares of the biopharmaceutical company's stock after selling 1,949 shares during the quarter. Aware Super Pty Ltd as trustee of Aware Super's holdings in Regeneron Pharmaceuticals were worth $592,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. E Fund Management Hong Kong Co. Ltd. boosted its position in Regeneron Pharmaceuticals by 344.4% during the 1st quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 31 shares during the period. Activest Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Finally, Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on REGN shares. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. Raymond James Financial upgraded shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research note on Tuesday, September 2nd. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. Sanford C. Bernstein boosted their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Finally, Morgan Stanley lowered their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating for the company in a research note on Friday, October 10th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $817.88.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $576.42 on Thursday. The firm has a fifty day moving average of $574.15 and a two-hundred day moving average of $563.61. The firm has a market cap of $61.09 billion, a P/E ratio of 14.53, a P/E/G ratio of 1.84 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,020.55. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $11.56 earnings per share. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.